Literature DB >> 11709805

Aldosterone in progressive renal disease.

T H Hostetter1, M E Rosenberg, H N Ibrahim, I Juknevicius.   

Abstract

Blockade of the renin-angiotensin-aldosterone system has proven effective in retarding progression of renal disease in the remnant kidney model, as well as other experimental diseases, and, most importantly, in a range of progressive human renal diseases. Attention has focused on the role of angiotensin II (Ang II) in propagating progression both by its hemodynamic and nonhemodynamic actions. Recent evidence, predominately in the remnant kidney model, indicates that the drugs used to block this hormone system, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, also lower aldosterone levels. Thus, aldosterone, as well as angiotensin II, appears to be instrumental in sustaining the hypertension and fibroproliferative destruction of the residual kidney. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709805     DOI: 10.1053/snep.2001.26797

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  10 in total

Review 1.  Aldosterone-induced fibrosis in the kidney: questions and controversies.

Authors:  Andrew S Brem; David J Morris; Rujun Gong
Journal:  Am J Kidney Dis       Date:  2011-06-25       Impact factor: 8.860

2.  Heme oxygenase activity as a determinant of the renal hemodynamic response to low-dose ANG II.

Authors:  Karl A Nath; Melissa C Hernandez; Anthony J Croatt; Zvonimir S Katusic; Luis A Juncos
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-08-11       Impact factor: 3.619

3.  Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury.

Authors:  Wai Yan Sun; Bo Bai; Cuiting Luo; Kangmin Yang; Dahui Li; Donghai Wu; Michel Félétou; Nicole Villeneuve; Yang Zhou; Junwei Yang; Aimin Xu; Paul M Vanhoutte; Yu Wang
Journal:  JCI Insight       Date:  2018-09-06

4.  Oxidative damages in tubular epithelial cells in IgA nephropathy: role of crosstalk between angiotensin II and aldosterone.

Authors:  Joseph C K Leung; Loretta Y Y Chan; Sydney C W Tang; Man-Fai Lam; Chui-Wa Chow; Ai-Ing Lim; Kar-Neng Lai
Journal:  J Transl Med       Date:  2011-10-06       Impact factor: 5.531

5.  Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.

Authors:  Lene Boesby; Thomas Elung-Jensen; Tobias Wirenfeldt Klausen; Svend Strandgaard; Anne-Lise Kamper
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

6.  Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease.

Authors:  Weisong Wang; Lihua Li; Zhonghai Zhou; Junjie Gao; Yinghao Sun
Journal:  Exp Ther Med       Date:  2013-10-09       Impact factor: 2.447

7.  Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan.

Authors:  Atieh Makhlough; Zahra Kashi; Ozra Akha; Ehsan Zaboli; Jamshid Yazdanicharati
Journal:  Nephrourol Mon       Date:  2014-01-14

Review 8.  The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.

Authors:  Luxitaa Goenka; Raghavan Padmanaban; Melvin George
Journal:  Curr Clin Pharmacol       Date:  2019

9.  Ultrasonographic Detected Adrenomegaly in Clinically Ill Cats: A Retrospective Study.

Authors:  João Oliveira; Maria Joana Dias; Ana Paula Fontes; Ryane E Englar; Gonçalo Vicente; Rui Lemos Ferreira; Sara Galac; Rodolfo Oliveira Leal
Journal:  Vet Sci       Date:  2022-08-09

10.  The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial.

Authors:  Hitoshi Minakuchi; Shu Wakino; Hidenori Urai; Arata Kurokochi; Kazuhiro Hasegawa; Takeshi Kanda; Hirobumi Tokuyama; Hiroshi Itoh
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.